Abstract
Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1 levels and responses to meals may be altered in obese subjects. Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes. Thus, GLP-1 RAs may provide a new option for pharmacological treatment of obesity.
| Original language | English |
|---|---|
| Journal | International journal of obesity (2005) |
| Volume | 37 |
| Issue number | 9 |
| Pages (from-to) | 1161-8 |
| Number of pages | 8 |
| ISSN | 0307-0565 |
| DOIs | |
| Publication status | Published - Sept 2013 |
Keywords
- Animals
- Eating
- Gastric Inhibitory Polypeptide
- Glucagon-Like Peptide 1
- Humans
- Hyperglycemia
- Hypoglycemic Agents
- Incretins
- Obesity
- Peptides
- Receptors, Glucagon
- Satiation
- Signal Transduction
- Venoms
- Weight Loss
